Cabergoline 1 mg as a Single Dose for Lactation Suppression
For a 33-year-old woman not breastfeeding who desires medication to suppress lactation, cabergoline 1 mg given as a single oral dose is the preferred pharmacologic option 1, 2.
Rationale for Cabergoline
The 2025 BJOG Green-Top Guideline (Grade 1A recommendation) explicitly states that cabergoline is superior to bromocriptine and no treatment, with better tolerability and significantly lower rates of rebound breast activity 1. This recommendation is based on a double-blind RCT of 272 women comparing single-dose cabergoline (1 mg) with bromocriptine (2.5 mg twice daily for 14 days), which demonstrated similar effectiveness but with cabergoline being simpler to use and having fewer adverse events 1.
The Society of Family Planning 2025 guideline reinforces this, noting that cabergoline 1 mg given within 1 day is "effective, well tolerated, and superior to bromocriptine for suppressing lactation and minimizing adverse effects" 2.
Dosing and Administration
- Dose: 1 mg orally as a single dose
- Timing: Administer within 24 hours after delivery (or when lactation suppression is desired)
- Duration: Single dose only—this is a major advantage over bromocriptine which requires 14 days of treatment
Important Contraindications and Precautions
Screen for these contraindications before prescribing:
- Uncontrolled hypertension or pre-eclampsia
- History of cardiac valvular disorders
- Known hypersensitivity to ergot derivatives
Special Consideration for Hypertensive Patients
If the patient has hypertension or pre-eclampsia, carefully weigh risks versus benefits 1. While dopamine agonists can increase blood pressure and have been associated with intracerebral hemorrhage, observational data from 85 women with late IUFD and hypertensive disorders showed no adverse maternal effects 1. If you proceed with cabergoline in a hypertensive patient, ensure close blood pressure monitoring, particularly in the first few days.
Alternative Approaches
If Cabergoline is Contraindicated or Unavailable:
Bromocriptine: 2.5 mg orally twice daily for 14 days 1
- Requires blood pressure monitoring, especially during the first days of treatment
- Higher rates of rebound lactation and adverse effects compared to cabergoline
- The 14-day regimen is less convenient for patients
Conservative Measures (First-Line for Mild Symptoms):
Before discussing pharmacologic options, counsel on simple physical measures 1:
- Supportive, well-fitting bra (not tight binding, which increases discomfort)
- Ice packs applied to breasts
- Analgesics (acetaminophen or NSAIDs) for pain
- Avoid nipple stimulation
- Fluid restriction is not necessary
Important caveat: Up to one-third of women experience severe breast pain despite conservative measures, making pharmacologic intervention reasonable 1.
Clinical Pitfalls to Avoid
Don't use estrogen preparations: While older trials showed effectiveness, estrogens are associated with increased risk of postpartum thromboembolism and are not recommended 1, 3
Don't prescribe bromocriptine as first-line: The single-dose convenience and superior safety profile of cabergoline makes it preferable when pharmacologic suppression is indicated
Don't overlook patient counseling: Many women (about 50%) receive inadequate information about lactation suppression 1. Discuss both conservative and pharmacologic options upfront
Don't forget to document contraindications: Specifically ask about hypertension, pre-eclampsia, and cardiac valve disease before prescribing
Expected Timeline
- With cabergoline: Lactation typically suppressed within 4-5 days
- With conservative measures alone: Lactation ceases after 1-2 weeks, with success in approximately 60-70% of women 4, 3
- Complete inhibition up to day 14 achieved in 90.2% of women receiving cabergoline 1 mg 5
When to Consider No Medication
If the patient has only mild breast discomfort and no contraindications to waiting, conservative management with analgesics and supportive measures is reasonable 3. The discomfort is self-limited and typically resolves within 1-2 weeks without intervention.